PLUR — Pluri Inc.
NASDAQ · Healthcare · Biotechnology
$1.46
-$0.01 (-0.68%)
Pluri Inc. (PLUR) is a biotechnology company listed on NASDAQ. It is led by Yaacov Yanay, based in MATAM Advanced Technology Park, Haifa, Israel, 3508409, with about 127 employees. Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Latest reported PLUR revenue for 2025-09-30 was $316.0K. Net income was -$6.1M. Revenue was down 76.3% from 2025-06-30 to 2025-09-30. PLUR currently screens at market cap $24.3M.
Use this PLUR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PLUR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PLUR SEC filings page. Lician reads the product cache first so this HTML stays unique to Pluri Inc. even when a live quote feed is slow.
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
PLUR Key Statistics
Market Cap
$24.28M
Volume
18,950
Previous Close
$1.56
Day Range
$1.57 – $1.67
P/B Ratio
306.56
EPS
-$3.56
Revenue
$1.34M
Net Income
-$23.25M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+309.8%
Profit Margin
-1740.3%
Employees
127
PLUR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.34M | $326.00K | $287.00K | $234.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$23.25M | -$21.34M | -$28.89M | -$41.37M |
| EPS (Diluted) | -$3.56 | -$3.99 | -$6.24 | -$1.28 |
Total Assets
$38.68M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.89M
Operating Cash Flow
-$18.21M
Free Cash Flow
$0.00
Pluri Inc. Company Information
- President, CEO & Director
- Yaacov Yanay
- Headquarters
- MATAM Advanced Technology Park, Haifa, Israel, 3508409
- Website
- www.pluri-biotech.com
- Phone
- 972 74 710 8600
- IPO / Founded
- 2003-06-30
- Sector
- Healthcare
- Industry
- Biotechnology